HK1203377A1 - Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent - Google Patents

Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent Download PDF

Info

Publication number
HK1203377A1
HK1203377A1 HK15103952.3A HK15103952A HK1203377A1 HK 1203377 A1 HK1203377 A1 HK 1203377A1 HK 15103952 A HK15103952 A HK 15103952A HK 1203377 A1 HK1203377 A1 HK 1203377A1
Authority
HK
Hong Kong
Prior art keywords
treatment
chemically modified
postpartum haemorrhage
heparan sulphate
modified heparin
Prior art date
Application number
HK15103952.3A
Other languages
English (en)
Chinese (zh)
Inventor
‧埃克曼-奧德貝格
G‧埃克曼-奥德贝格
‧馬爾姆斯特倫
A‧马尔姆斯特伦
Original Assignee
迪乐方有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 迪乐方有限责任公司 filed Critical 迪乐方有限责任公司
Publication of HK1203377A1 publication Critical patent/HK1203377A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15103952.3A 2012-05-08 2013-05-07 Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent HK1203377A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644036P 2012-05-08 2012-05-08
US61/644,036 2012-05-08
US201261668150P 2012-07-05 2012-07-05
US61/668,150 2012-07-05
PCT/SE2013/050510 WO2013169194A1 (en) 2012-05-08 2013-05-07 Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent

Publications (1)

Publication Number Publication Date
HK1203377A1 true HK1203377A1 (en) 2015-10-30

Family

ID=49551063

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103952.3A HK1203377A1 (en) 2012-05-08 2013-05-07 Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent

Country Status (16)

Country Link
US (1) US20150099703A1 (enExample)
EP (1) EP2846810A4 (enExample)
JP (1) JP2015516415A (enExample)
CN (1) CN104284667A (enExample)
AU (1) AU2013260209A1 (enExample)
BR (1) BR112014027712B1 (enExample)
CA (1) CA2868403A1 (enExample)
HK (1) HK1203377A1 (enExample)
IL (1) IL234752A0 (enExample)
MX (1) MX2014013449A (enExample)
MY (1) MY192330A (enExample)
NZ (1) NZ701419A (enExample)
RU (1) RU2014149230A (enExample)
SG (1) SG11201407346WA (enExample)
UA (1) UA117912C2 (enExample)
WO (1) WO2013169194A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12502403B2 (en) 2020-02-17 2025-12-23 Dilafor Ab Tafoxiparin for the treatment of preeclampsia
CA3255831A1 (en) 2022-05-03 2023-11-09 Dilafor Ab NEW MEDICAL USE OF TAFOXIPARIN
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993810A (en) * 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
SE521676C2 (sv) * 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
UA21707U (en) * 2006-12-18 2007-03-15 Valerii Ivanovych Linnikov Method for preventing and treating thrombophilia in course of gestation and postpartum
US8445436B2 (en) * 2007-12-03 2013-05-21 Florida State University Research Foundation, Inc. Oxytocin and melatonin compositions and associated methods for inducing labor
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
DK2794665T3 (da) * 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
CN104203256B (zh) * 2012-03-26 2017-11-24 迪乐方有限责任公司 用于引产的包含硫酸化的葡糖胺聚糖的联合治疗
NZ631279A (en) * 2012-03-26 2016-06-24 Dilafor Ab Method for treatment of labor arrest

Also Published As

Publication number Publication date
RU2014149230A (ru) 2016-06-27
AU2013260209A1 (en) 2014-11-20
MX2014013449A (es) 2014-12-08
CN104284667A (zh) 2015-01-14
JP2015516415A (ja) 2015-06-11
CA2868403A1 (en) 2013-11-14
WO2013169194A1 (en) 2013-11-14
UA117912C2 (uk) 2018-10-25
US20150099703A1 (en) 2015-04-09
NZ701419A (en) 2016-04-29
SG11201407346WA (en) 2014-12-30
EP2846810A1 (en) 2015-03-18
IL234752A0 (en) 2014-11-30
MY192330A (en) 2022-08-17
BR112014027712A2 (pt) 2017-06-27
BR112014027712B1 (pt) 2023-12-19
EP2846810A4 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
WO2014093489A3 (en) Hydrogel membrane for adhesion prevention
AR096438A1 (es) Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
HK1203370A1 (en) Method for treatment of labor arrest
WO2014078458A3 (en) Occlusive devices
MX2015013727A (es) Composicion para preparacion de uso externo con permeabilidad transdermica mejorada.
TN2014000236A1 (en) Use of chemically modified heparin derivates in sickle cell disease
PL2429515T3 (pl) Nowe leki do stosowania miejscowego oparte na siarczanowanym kwasie hialuronowym jako środku aktywującym lub inhibitującym aktywność cytokin
PH12015501045A1 (en) Bpo wash gel composition
FI3613421T3 (fi) Asetyylisalisyylihappo tromboembolisen tapahtuman riskin pienentämiseksi
HK1217720A1 (zh) 选择性递送分子及使用方法
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
EP3380088A4 (en) USE OF MICRO-RNA 146A AND NANOCERIA CONJUGATE TO IMPROVE WOUND HEALING AND PROMOTE TISSUE GENERATION
WO2014153009A3 (en) Thiosaccharide mucolytic agents
EP3980017A4 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
HK1203369A1 (en) Combination treatment comprising sulphated glycosaminoglycans for inducing labor
WO2008012107A3 (en) Use of polyethylene glycol in inflammatory skin conditions and wound healing
MX373541B (es) Gel de acido salicilico.
MX2015001508A (es) El uso de antitrombina en la oxigenacion por membrana extracorporea.
MX2014013449A (es) Tratamiento de la hemorragia postparto (pph) con heparina modificada quimicamente o sulfato de heparan y un agente uterotonico.
HK1204964A1 (en) Modulation of factor xa inhibitor mediated blood loss by partial and transient administration of antidote
MX363389B (es) Composicion farmaceutica que comprende ivabradina amorfa.
MX2015009348A (es) Composiciones hemostaticas.
PL2640364T3 (pl) Kompozycja farmaceutyczna zawierająca sól wodorowęglanową i jej zastosowanie jako leku w leczeniu i/lub profilaktyce kamicy moczowej i chorób pokrewnych
WO2010099319A3 (en) Composition and methods for clotting blood
WO2012061811A3 (en) Anti- connective tissue growth factor agent for use in the treatment of lung remodeling disease